{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:40:19Z","timestamp":1777761619344,"version":"3.51.4"},"posted":{"date-parts":[[2025,9,15]]},"group-title":"In Review","reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T00:00:00Z","timestamp":1757894400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,8,30]]},"abstract":"<title>Abstract<\/title>\n                <p>Background.\nClinical trial failure \u2014when a study is withdrawn or terminated for reasons unrelated to safety or efficacy\u2014 wastes resources and exposes patients to unnecessary risks. We examined such failures in the field of multiple sclerosis (MS).\nMethods.\nWe searched ClinicalTrials.gov for phase III and IV MS drug trials conducted in 2008\u20132024. Trials were classified as normally ended or failed based on recruitment status and reported reasons. When information was missing, we reviewed publications and contacted principal investigators (PIs). Kaplan-Meier method was used to assess time to trial end and multivariate logistic regression was used to identify factors associated with failure.\nResults.\nThe 282 clinical trials included in our analysis involved 62 experimental drugs, primarily disease-modifying therapies (n\u2009=\u2009213 trials). Most studies aimed to evaluate drug efficacy (n\u2009=\u2009196 trials). Overall, 74.8% trials ended normally while 25.2% failed. On average, failed trials ended ten months earlier that the rest of studies (trial actual duration: 17.8 vs. 28.2 months, p\u2009&lt;\u20090.001). Main reasons for failure were low recruitment (28.2%), unspecified business decisions (26.8%) and logistical problems (12.7%). In 28.2% of occasions it remained undisclosed. Trials evaluating drug safety (OR 0.35, 95%CI 0.13\u20130.94) and those with \u2265\u200950 centres (OR 0.10, 95%CI 0.02\u20130.38) failed less often. Failure was not associated with other factors such as study start date, PI location or industry involvement.\nConclusions.\nOne out of four MS clinical trials fails. Increasing the number of study sites and improving recruitment strategies could enhance their success rates.<\/p>","DOI":"10.21203\/rs.3.rs-7496530\/v1","type":"posted-content","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:24:56Z","timestamp":1757917496000},"source":"Crossref","is-referenced-by-count":0,"title":["Determinants of clinical trial failure in multiple sclerosis: insights from ClinicalTrials.gov"],"prefix":"10.21203","author":[{"given":"Alejandro","family":"Rivero-de-Aguilar","sequence":"first","affiliation":[{"name":"University of Santiago de Compostela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"P\u00e9rez-R\u00edos","sequence":"additional","affiliation":[{"name":"University of Santiago de Compostela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph S.","family":"Ross","sequence":"additional","affiliation":[{"name":"Yale School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Mascare\u00f1as-Garc\u00eda","sequence":"additional","affiliation":[{"name":"University of Santiago de Compostela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ruano-Ravi\u00f1a","sequence":"additional","affiliation":[{"name":"University of Santiago de Compostela"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Varela-Lema","sequence":"additional","affiliation":[{"name":"University of Santiago de Compostela"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"10092","key":"ref1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S0140-6736(16)31592-6","article-title":"Progress in evidence-based medicine: a quarter century on","volume":"390","author":"Djulbegovic B","year":"2017","unstructured":"Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415\u201323.","journal-title":"Lancet"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nrd.2017.70","article-title":"How much do clinical trials cost?","volume":"16","author":"Martin L","year":"2017","unstructured":"Martin L, Hutchens M, Hawkins C, Radnov A. How much do clinical trials cost? Nat Rev Drug Discov. 2017;16(6):381\u20132.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/cts.12980","article-title":"Approval success rates of drug candidates based on target, action, modality, application, and their combinations","volume":"14","author":"Yamaguchi S","year":"2021","unstructured":"Yamaguchi S, Kaneko M, Narukawa M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin Transl Sci. 2021;14(3):1113\u201322.","journal-title":"Clin Transl Sci"},{"key":"ref4","article-title":"World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants","author":"World Medical Association","year":"2024","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2024.","journal-title":"JAMA"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1740774514558307","article-title":"Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials","volume":"12","author":"Carlisle B","year":"2015","unstructured":"Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clin Trials. 2015;12(1):77\u201383.","journal-title":"Clin Trials"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00228-022-03437-5","article-title":"Premature termination of clinical trials in Spain: reasons, characteristics, and opportunities to improve","volume":"79","author":"Filippi-Arriaga F","year":"2023","unstructured":"Filippi-Arriaga F, Boy RJ, Del Gobbo AD, Gallego AR. Premature termination of clinical trials in Spain: reasons, characteristics, and opportunities to improve. Eur J Clin Pharmacol. 2023;79(2):249\u201356.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jama.2014.1361","article-title":"Prevalence, Characteristics, and Publication of Discontinued Randomized Trials","volume":"311","author":"Kasenda B","year":"2014","unstructured":"Kasenda B, von Elm E, You J, Bl\u00fcmle A, Tomonaga Y, Saccilotto R, et al. Prevalence, Characteristics, and Publication of Discontinued Randomized Trials. JAMA. 2014;311(10):1045.","journal-title":"JAMA"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/JU.0000000000002206","article-title":"Considerations in the Analysis of Clinical Trial Failure","volume":"207","author":"Stensland KD","year":"2022","unstructured":"Stensland KD, Daignault-Newton S, Skolarus TA. Considerations in the Analysis of Clinical Trial Failure. J Urol. 2022;207(1):9\u201311.","journal-title":"J Urol"},{"key":"ref9","article-title":"Multiple sclerosis","author":"Jakimovski D","year":"2023","unstructured":"Jakimovski D, Bittner S, Zivadinov R, Morrow SA, Benedict RH, Zipp F et al. Multiple sclerosis. Lancet. 2023.","journal-title":"Lancet"},{"issue":"10","key":"ref10","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1177\/13524585241265961","article-title":"The first global landscape analysis of multiple sclerosis research funding","volume":"30","author":"Bebo B","year":"2024","unstructured":"Bebo B, Coetzee T, Gray E, Helme A, Kanellis P, Landsman D, et al. The first global landscape analysis of multiple sclerosis research funding. Mult Scler J. 2024;30(10):1363\u20139.","journal-title":"Mult Scler J"},{"issue":"9","key":"ref11","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju229","article-title":"Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?","volume":"106","author":"Stensland KD","year":"2014","unstructured":"Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N et al. Adult Cancer Clinical Trials That Fail to Complete: An Epidemic? JNCI J Natl Cancer Inst. 2014;106(9).","journal-title":"JNCI J Natl Cancer Inst"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ijcard.2017.06.020","article-title":"Discontinuation and non-publication of clinical trials in cardiovascular medicine","volume":"244","author":"Roddick AJ","year":"2017","unstructured":"Roddick AJ, Chan FTS, Stefaniak JD, Zheng SL. Discontinuation and non-publication of clinical trials in cardiovascular medicine. Int J Cardiol. 2017;244:309\u201315.","journal-title":"Int J Cardiol"},{"key":"ref13","unstructured":"ClinicalTrials.gov. Glossary of Common Site Terms [Internet]. [cited 2024 Sep 14]. Available from: https:\/\/clinicaltrials.gov\/study-basics\/glossary"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"e017719","DOI":"10.1136\/bmjopen-2017-017719","article-title":"Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis","volume":"7","author":"Jones CW","year":"2017","unstructured":"Jones CW, Safferman MR, Adams AC, Platts-Mills TF. Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis. BMJ Open. 2017;7(10):e017719.","journal-title":"BMJ Open"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke JF","year":"1983","unstructured":"Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444\u20131444.","journal-title":"Neurology"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, Cutter GR, S\u00f8rensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson AJ","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"10","key":"ref18","doi-asserted-by":"crossref","first-page":"102775","DOI":"10.1016\/j.cpcardiol.2024.102775","article-title":"Analysis of terminated pulmonary hypertension clinical trials. What are we doing wrong?","volume":"49","author":"Abdulelah M","year":"2024","unstructured":"Abdulelah M, Abdulelah ZA, Azzam M, Ghalayni R, Kawtharany H, Khraisat F, et al. Analysis of terminated pulmonary hypertension clinical trials. What are we doing wrong? Curr Probl Cardiol. 2024;49(10):102775.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ehf2.13099","article-title":"Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results","volume":"8","author":"Khan MS","year":"2021","unstructured":"Khan MS, Shahid I, Asad N, Greene SJ, Khan SU, Doukky R, et al. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results. ESC Hear Fail. 2021;8(1):16\u201325.","journal-title":"ESC Hear Fail"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"5517","DOI":"10.1002\/cam4.5385","article-title":"Early Termination of Oncology Clinical Trials in the United States","volume":"12","author":"Zhang E","year":"2023","unstructured":"Zhang E, DuBois SG. Early Termination of Oncology Clinical Trials in the United States. Cancer Med. 2023;12(5):5517\u201325.","journal-title":"Cancer Med"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12876-022-02592-4","article-title":"Assessing clinical trial failure risk factors and reasons in gastric cancer","volume":"22","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Yin J, Yue Y, Su Y, Jiang H. Assessing clinical trial failure risk factors and reasons in gastric cancer. BMC Gastroenterol. 2022;22(1):496.","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"ref22","first-page":"154","article-title":"Estimating the rate and reasons of clinical trial failure in urologic oncology","volume":"39","author":"Stensland KD","year":"2021","unstructured":"Stensland KD, DePorto K, Ryan J, Kaffenberger S, Reinstatler LS, Galsky M, et al. Estimating the rate and reasons of clinical trial failure in urologic oncology. Urol Oncol Semin Orig Investig. 2021;39(3):154\u201360.","journal-title":"Urol Oncol Semin Orig Investig"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1016\/j.jse.2022.02.030","article-title":"Analysis of the frequency, characteristics, and reasons for termination of shoulder- and elbow-related clinical trials","volume":"31","author":"Caruana DL","year":"2022","unstructured":"Caruana DL, Gouzoulis MJ, McLaughlin WM, Grauer JN. Analysis of the frequency, characteristics, and reasons for termination of shoulder- and elbow-related clinical trials. J Shoulder Elb Surg. 2022;31(9):1922\u20138.","journal-title":"J Shoulder Elb Surg"},{"issue":"7","key":"ref24","doi-asserted-by":"crossref","first-page":"E596","DOI":"10.1097\/BSD.0000000000001323","article-title":"Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials","volume":"35","author":"Caruana DL","year":"2022","unstructured":"Caruana DL, Nam-Woo Kim D, Galivanche AR, David WB, Justen MA, Moushey AM, et al. Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials. Clin Spine Surg Spine Publ. 2022;35(7):E596\u2013600.","journal-title":"Clin Spine Surg Spine Publ"},{"issue":"dec09 1","key":"ref25","doi-asserted-by":"crossref","first-page":"g6870","DOI":"10.1136\/bmj.g6870","article-title":"Discontinuation and non-publication of surgical randomised controlled trials: observational study","volume":"349","author":"Chapman SJ","year":"2014","unstructured":"Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A. Discontinuation and non-publication of surgical randomised controlled trials: observational study. BMJ. 2014;349(dec09 1):g6870\u20136870.","journal-title":"BMJ"},{"issue":"3","key":"ref26","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0223","article-title":"Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children","volume":"138","author":"Pica N","year":"2016","unstructured":"Pica N, Bourgeois F. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics. 2016;138(3).","journal-title":"Pediatrics"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"djv324","DOI":"10.1093\/jnci\/djv324","article-title":"Predicting Low Accrual in the National Cancer Institute\u2019s Cooperative Group Clinical Trials","volume":"108","author":"Bennette CS","year":"2016","unstructured":"Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute\u2019s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2):djv324.","journal-title":"J Natl Cancer Inst"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jclinepi.2016.07.016","article-title":"A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable","volume":"80","author":"Briel M","year":"2016","unstructured":"Briel M, Olu KK, von Elm E, Kasenda B, Alturki R, Agarwal A, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8\u201315.","journal-title":"J Clin Epidemiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review","volume":"11","author":"Fogel DB","year":"2018","unstructured":"Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156\u201364.","journal-title":"Contemp Clin Trials Commun"},{"key":"ref30","first-page":"2","article-title":"Strategies to improve recruitment to randomised trials","volume":"2018","author":"Treweek S","year":"2018","unstructured":"Treweek S, Pitkethly M, Cook J, Fraser C, Mitchell E, Sullivan F, et al. Strategies to improve recruitment to randomised trials. Cochrane Database Syst Rev. 2018;2018:2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12916-018-1017-7","article-title":"Adaptive designs in clinical trials: why use them, and how to run and report them","volume":"16","author":"Pallmann P","year":"2018","unstructured":"Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Med. 2018;16(1):29.","journal-title":"BMC Med"},{"key":"ref32","unstructured":"ClinicalTrials.gov. Trends and Charts on Registered Studies. [Internet]. [cited 2025 Apr 5]. Available from: https:\/\/clinicaltrials.gov\/about-site\/trends-charts"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7496530\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7496530\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:20:38Z","timestamp":1777472438000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7496530\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,15]]},"references-count":32,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7496530\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1159\/000551962","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,9,15]]},"subtype":"preprint"}}